ClinicalTrials.gg
Sign In
Drug

Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543 clinical trials

Also written JNJ-80948543.

studies test it
3
open now
1
in phase 3
0
first study started
2022

How each study uses Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorisations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

JNJ-80948543
3

Studies by the year they started

3 studies that test it; most in 2024 (2)

Studies that test Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543, by start year
YearStudies
20221
20242

By phase

A phase 1/2 study counts in both.

Phase 1
3

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Lymphoma, Non-Hodgkin
2
Leukemia, Myeloid, Acute
1

Who runs them

Industry 3 · Other 0

Janssen Research & Development, LLC (3)

Often tested with

Tested in the same studies.

Rezetamig (1) · Safimaltib (1) · Ibrutinib (1) · JNJ-64264681 (1) · DHODH Inhibitor JNJ-74856665 (1) · Anti-TMEFF2/Anti-CD3 Bispecific Antibody JNJ-70218902 (1) · JNJ-64619178 (1) · JNJ-87801493 (1)

Studies

Open first, then newest update. How each study uses Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 3

Given beside what is tested · 1 — Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543 is usual care or a partner of the new treatment